Skip to main content
Clinical Trials/NCT06384755
NCT06384755RecruitingNot Applicable

Evaluation of a Norwegian Adaptation of the Honest Open Proud Program for Adults With Psychotic and Bipolar Disorders in an Outpatient Setting

Oslo University Hospital4 sites in 1 country40 target enrollmentStarted: April 20, 2024Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
40
Locations
4
Primary Endpoint
Stigma Stress Scale (Rüsch, Corrigan, Wassel et al., 2009; Rüsch, Corrigan, Powell et al., 2009)

Study Overview

Brief Summary

The purpose of this pilot study is to evaluate the feasibility, acceptability and efficacy of a Norwegian adaptation of the group-based intervention 'Honest Open Proud' among adults with psychotic and bipolar disorders in an outpatient setting.

Detailed Description

Because people with mental illness experience both public and personal stigma, which is related to lower levels of recovery and wellbeing, it is common to struggle with decisions regarding potential disclosure of mental health difficulties or diagnoses. There are pros and cons with both disclosure and secrecy. Disclosure can lead to social support, followed by improved mental health and reduced public stigma, but also stigmatization and social exclusion. Secrecy can prevent stigmatization but may also lead to social isolation and thus poorer mental health and increased public stigma. Therefore, people with mental illness need help to make strategic decisions about whether, and if so, to whom, when and how they wish to disclose their mental health problems. As contact with other people with mental health difficulties is crucial to anti-stigma interventions, people with mental illness could benefit from meeting peers, especially as role models. This suggests that peer facilitators could be an important feature in a program aiming to help people with mental illness handle stigma and challenges related to disclosure. The Honest Open Proud (HOP) program was developed for this purpose. Because people with psychotic and bipolar disorders experience particularly high levels of both public and personal stigma, which negatively impacts their recovery rates, they may be especially in need of the HOP program.

The investigators aim to evaluate whether a Norwegian adaptation of the HOP group program, which is facilitated by peers, is feasible and acceptable for people with psychotic and bipolar disorders in an outpatient setting. Moreover, whether it helps them handle stigma and disclosure related decisions.

The investigators propose a pilot randomized controlled trial, comparing an intervention group receiving a 6-week Norwegian adaptation of the HOP program to a waiting list control group. Both groups receive treatment as usual. The main research question is whether this intervention is feasible and acceptable. However, efficacy measures tapping change in stigma and disclosure distress, as well as recovery and wellbeing, from before to after the intervention, were included. The aim is to find what effect sizes can be expected in future larger studies in Norway, rather than to find significant differences in effect sizes.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosed current psychotic (F 20) or bipolar disorder (F 30) according to International Classification of Diseases 10th Revision (ICD-10)
  • Age 18 to 65
  • Ability to provide written informed consent.
  • Fluent in Norwegian (needed for self-report measures)
  • Experience difficulties with stigma and disclosure regarding mental illness.

Exclusion Criteria

  • Intellectual disability
  • Organic disorders

Outcomes

Primary Outcomes

Stigma Stress Scale (Rüsch, Corrigan, Wassel et al., 2009; Rüsch, Corrigan, Powell et al., 2009)

Time Frame: Change from T0 to T1 and T2 (assessed at T0 = week 0; T1 =week 3; T2 = week 6)

8 items, from 1 (strongly disagree) to 7 (strongly agree)

Secondary Outcomes

  • Satisfaction with life (Lehman, 1988)(Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6))
  • The Questionnaire about the Process of Recovery - 15 (QPR-15) (Niel et al 2007)(Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6))
  • Internalised Stigma of Mental Illness Inventory (ISMI-10) (Boyd, Otilingam, & Deforge, 2014)(Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6))
  • Generalized Anxiety disorder (GAD-7) (Spitzer et al, 2006)(Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6))
  • Disclosure Distress (Rüsch et al., 2014a)(Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6))
  • Warwick and Edinburgh Wellbeing Scale (WEMWBS) (Tennant et al 2007)(Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6))
  • Patient Health Questionnaire-4 (PHQ-9) (Kroenke et al 2009)(Change from T0 to T2 (assessed at T0 = week 0; T2 = week 6))

Investigators

Sponsor
Oslo University Hospital
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Carmen Simonsen

Associate Professor

Oslo University Hospital

Study Sites (4)

Loading locations...

Similar Trials

Honest Open Proud for Psychotic and... | Clinical Trial